Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma

Samuel, Didier; Colombo, Massimo; El-Serag, Hashem; Sobesky, Rodolphe; Heaton, Nigel

doi:10.1002/lt.22423

Cited by 53 publications

(41 citation statements)

References 51 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the current use of hepatectomy and liver transplantation to improve the radical cure rates, the long-term outcome for HCC patients after effective treatment still remains generally poor [2]. The main reason for the high early recurrence of HCC is the high potential for vascular invasion and metastasis [3,4].…”

Section: Introductionmentioning

confidence: 98%

Protocadherin 9 inhibits epithelial–mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma

Zhu

Yang

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Protocadherin 9 (PCDH9) was found frequently lost in hepatocellular carcinoma (HCC). Here we investigated the role of PCDH9 in the development of HCC. We confirmed that PCDH9 was down-regulated in HCC tissues and cell lines compared with the adjacent non-tumor tissues. PCDH9 downregulation was significantly associated with malignant portal vein invasion of HCC patients. Gain- and loss-of-function studies revealed that downregulation of PCDH9 facilitated tumor cell migration and epithelial-mesenchymal transition (EMT). We identified PCDH9 as a novel regulator of EMT by increasing the activity of GSK-3β and inhibiting Snail1, indicating its potential therapeutic value for reducing metastasis of HCC.

show abstract

Section: Introductionmentioning

confidence: 98%

Protocadherin 9 inhibits epithelial–mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma

Zhu

Yang

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

show abstract

“…Hepatocellular cancer (HCC) is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related death [1][2][3]. Liver transplantation (LT) is the therapeutic gold standard in cirrhotic patients having HCC fulfilling the Milan criteria (MC) [4].…”

Section: Introductionmentioning

confidence: 99%

Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West

Lai¹,

Avolio²,

Lerut³

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

“…1 This growth in the demand for liver transplantation will continue to place a strain on the already limited supply of donor organs. 2 In order to bridge the gap between the limited organ supply and the pool of waiting-list candidates, many transplant programs have regained interest in procuring organs from donation after cardiac death (DCD) donors. Recent reports have shown that DCD livers are used more frequently than donation after brain death (DBD) organs in patients with HCC (20.2% versus 13%).…”

mentioning

confidence: 99%

Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts

et al. 2013

View full text Add to dashboard Cite

The impact of ischemia/reperfusion injury in the setting of transplantation for hepatocellular carcinoma (HCC) has not been thoroughly investigated. The present study examined data from the Scientific Registry of Transplant Recipients for all recipients of deceased donor liver transplants performed between January 1, 1995 and October 31, 2011. In a multivariate Cox analysis, significant predictors of patient survival included the following: HCC diagnosis (P < 0.01), donation after cardiac death (DCD) allograft (P < 0.001), hepatitis C virus-positive status (P < 0.01), recipient age (P < 0.01), donor age (P < 0.001), Model for End-Stage Liver Disease score (P < 0.001), recipient race, and an alpha-fetoprotein level > 400 ng/mL at the time of transplantation. In order to test whether the decreased survival seen for HCC recipients of DCD grafts was more than would be expected because of the inferior nature of DCD grafts and the diagnosis of HCC, a DCD allograft/HCC diagnosis interaction term was created to look for potentiation of effect. In a multivariate analysis adjusted for all other covariates, this interaction term was statistically significant (P 5 0.049) and confirmed that there was potentiation of inferior survival with the use of DCD allografts in recipients with HCC. In conclusion, patient survival and graft survival were inferior for HCC recipients of DCD allografts versus recipients of donation after brain death allografts. This potentiation of effect of inferior survival remained even after adjustments for the inherent inferiority observed in DCD allografts as well as other known risk factors. It is hypothesized that this difference could reflect an increased rate of recurrence of HCC.

show abstract

Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma

Cited by 53 publications

References 51 publications

Protocadherin 9 inhibits epithelial–mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma

Protocadherin 9 inhibits epithelial–mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma

Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West

Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts

Contact Info

Product

Resources

About